Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1867 • ACR Convergence 2020
Two-Year Diagnostic Consistency in Patients with Chronic Back Pain Suspected of Axial Spondyloarthritis in Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Ulf Lindström⁴, Roberta Ramonda⁵, Marleen van de Sande⁶, Désirée van der Heijde⁷ and Floris van Gaalen⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁵University of Padova, Padova, Italy, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: A diagnosis of (early) axial spondyloarthritis (axSpA) is based on pattern recognition, which can be challenging and may change over time. The aim of…
Abstract Number: 1892 • ACR Convergence 2020
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for F Ankylosing Spondylitis (AS) Patients with the App of Smart System of Disease Management (SSDM): A Cohort Study from China
Jing Xue¹, Hongzhi Wang², Hongbin Li³, Hui Song⁴, Yasong Li⁵, Xiaofei Shi⁶, Hongjun Zhao⁷, Feng Wei⁸, Bing Wu⁹, Hui Xiao¹⁰, Yuhua Jia⁹, Fei Xiao⁹ and Huaxiang Wu¹, ¹The Second Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, China (People's Republic), ²The First Hospital of Jiaxing, Jiaxing, China (People's Republic), ³The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ⁴Beijing Jishuitan Hospital, Beijing, China (People's Republic), ⁵Zhejiang Provincial People's Hospital, Hangzhou, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of science and technology, Luoyang, China (People's Republic), ⁷Xiangya Hospital of Central South University, Changsha, China (People's Republic), ⁸Jiangmen Central Hospital Affiliated Jiangmen Hospital of Sun Yat-Sen University, Jiangmen, China (People's Republic), ⁹Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic), ¹⁰Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic)
Background/Purpose: Ankylosing Spondylitis Disease Activity Score (ASDAS) is adopted to evaluate the degree of disease activity and the inflammatory response in AS patients. ASDAS score…
Abstract Number: 0080 • ACR Convergence 2020
Understanding Ankylosing Spondylitis –
Arnd Kleyer¹, Milena Pachowsky², Louis Schuster¹, Larissa Valor-Mendez³, Georg Schett⁴, Axel Hueber⁵ and David Simon¹, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Orthopedic and Trauma Surgery, FAU Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁵Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany
Background/Purpose: Rheumatology is underrepresented in the medical training of students in Germany. [1] Tools and methods are needed to inspire young students for specialist training…
Abstract Number: 0455 • ACR Convergence 2020
HLA-B27 and Host Immune Response: Lessons from Reactive Arthritis
Sophie Wojcik¹, Davina Morris², Gillian Fitzgerald³, Steve Ramkissoon⁴, Nigil Haroon² and Robert Inman⁵, ¹UHN, Montreal, QC, Canada, ²University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, ⁴UHN, Toronto, ON, Canada, ⁵University Health Network, Toronto, ON, Canada
Background/Purpose: The natural history of reactive arthritis (ReA) remains poorly understood. Certain patients with ReA will go on to develop a chronic course while others…
Abstract Number: 1310 • ACR Convergence 2020
Gut Microbiome Changes Are Different Between Ankylosing Spondylitis and Inflammatory Bowel Disease, and Correlate with Disease Activity in Both Diseases
Peter Sternes¹, Laurel Brett², Julie Phipps³, Francesco Ciccia⁴, Erika de Guzman³, Mark Morrison⁵, Gerald Holtmann⁶, Eva Klingberg⁷, Carolyn McIvor², Helena Forsblad-d'Elia⁸ and Matthew Brown⁹, ¹Institute for Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia, Brisbane, Queensland, Australia, ²Department of Gastroenterology, Logan Hospital, Brisbane, Queensland, Australia, ³Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia, ⁴Dipartimento di Medicina di Precisione, Università della Campania L. Vanvitelli, Naples, Naples, Campania, Italy, ⁵University of Queensland Diamantina Institute, University of Queensland, Brisbane, Queensland, Australia, ⁶Department of Gastrenterology, Princess Alexandra Hospital, Brisbane, Queensland, Australia, ⁷Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Vastra Gotaland, Sweden, ⁸Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Vasterbottens Lan, Sweden, ⁹Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom
Background/Purpose: Multiple studies have confirmed that the gut and stool microbiome in ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are distinct from healthy controls,…
Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Nathan den Broeder¹, Michelle Mulder¹, Mark Wenink¹, Alfons den Broeder¹, Lise Verhoef², Frank van den Hoogen¹ and C.A.J Michielsens¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…
Abstract Number: 1868 • ACR Convergence 2020
Comparison of Quality of Life Between Chronic Back Pain Patients with and Without a Diagnosis of Axial Spondyloarthritis After 2-Year Protocolised Follow-up: Data from the Spondyloarthritis Caught Early Cohort
Anne Boel¹, Miranda van Lunteren², Karen Fagerli³, Sofia Exarchou⁴, Roberta Ramonda⁵, Marleen van de Sande⁶, Désirée van der Heijde⁷ and Floris van Gaalen⁸, ¹Leiden University Medical Centre, Hooge Zwaluwe, Netherlands, ²Leiden University Medical Centre, Weesp, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ⁵University of Padova, Padova, Italy, ⁶Amsterdam UMC, AMC/University of Amsterdam, Department of Rheumatology and Clinical Immunology, Amsterdam Infection & Immunity Institute and Amsterdam Rheumatology and Immunology Center (ARC), Amsterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center (LUMC), Leiden, Netherlands
Background/Purpose: The aim of this study was to compare quality of life (QoL) between chronic back pain (CBP) patients with and without a diagnosis of…
Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Corinne Miceli-Richard¹, Denis Poddubnyy², Atul Deodhar³, Weibin Bao⁴, Craig Parman⁵, Brian Porter⁶ and Effie Pournara⁵, ¹Paris Descartes University, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris, France, ²Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharmaceuticals Corporation, East Hannover, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…
Abstract Number: 0084 • ACR Convergence 2020
Clinical Characteristics of Patients with Rheumatism of Juvenile Onset and Adult Onset in the BIOBADAGUAY Cohort
Natalia Cabrera¹, Vannia Valinotti², Gabriela Avila-Pedretti¹, Sonia Cabrera², Patricia Melgarejo³, Zoilo Morel⁴, Lourdes Roman², Pedro Babak⁴, Rodrigo Acosta², Romina Glitz⁴, Darwin Cordovilla⁵, Roger Rolon⁴, Magali Zanotti-Cavazzoni¹, Marco Antonio Franco Britos⁶, Marcos Vazquez², Pedro Delgadillo⁴, Isabel Acosta², María del Carmen Martinez⁴, Gabriel Elizaur⁴, María Teresa Romero⁴, Ernesto Paredes⁴, Paloma de Abreu¹ and Leticia Segovia⁷, ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Hospital de Clínicas, Asunción, Paraguay, ³Hospital IPS, Villa Rica, Paraguay, ⁴Hospital Central del Instituto de Previsión Social, Asunción, Paraguay, ⁵Instituto Nacional de Reumatología, Montevideo, Uruguay, ⁶Instituto de Previsi�n Social, Asunci�n, Central, Paraguay, ⁷Hospital del IPS, Asunción, Paraguay
Background/Purpose: The Paraguayan-Uruguayan cohort of patients with rheumatic inflammatory diseases (BIOBADAGUAY), collect clinical and epidemiological information on adults and children patients receiving biological therapies (BT).…
Abstract Number: 0740 • ACR Convergence 2020
Card9 Promotes Th17-mediated Arthritis and Spondylitis via Control of Acute Pathogenic Neutrophil Responses in SKG Mice
Holly Rosenzweig¹, Emily Vance¹, Ellen Lee¹ and Ruth Napier¹, ¹Oregon Health & Science University and VA Portland Health Care System, Portland, OR
Background/Purpose: Caspase recruitment domain-containing protein 9 (CARD9) is an intracellular signal transduction molecule that mediates antimicrobial responses following activation of C-type lectin receptors (ie. Dectin-1) by…
Abstract Number: 1312 • ACR Convergence 2020
Time-dependent Analysis of Incident Extra-articular Manifestations and Comorbidities in Axial Spondyloarthritis
Gillian Fitzgerald¹, George Tomlinson², Steve Ramkissoon³, Sophie Wojcik⁴, Robert Inman⁵ and Nigil Haroon⁶, ¹Toronto Western Hospital, Toronto, ON, Canada, ²Department of Medicine, University Hospital Network, Toronto, Toronto, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴UHN, Montreal, QC, Canada, ⁵University Health Network, Toronto, ON, Canada, ⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) patients have higher morbidity and mortality compared to healthy controls. Much of this excess disease burden is related to extra-articular manifestations…
Abstract Number: 1364 • ACR Convergence 2020
Bimekizumab Long-Term Efficacy and Safety over 96 Weeks in Patients with Ankylosing Spondylitis: Interim Results from a Phase 2b Open-Label Extension Study
Xenofon Baraliakos¹, Atul Deodhar², Maxime Dougados³, Marga Oortgiesen⁴, Natasha de Peyrecave⁵, Martin Bauer⁶, Thomas Vaux⁵, Carmen Fleurinck⁷ and Désirée van der Heijde⁸, ¹Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, ²Oregon Health & Science University, Portland, OR, ³Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁴UCB Pharma, Raleigh, NC, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Bimekizumab (BKZ), a monoclonal antibody that selectively inhibits interleukin (IL)-17A and IL-17F, has demonstrated clinical efficacy in patients with ankylosing spondylitis (AS) treated over…
Abstract Number: 1869 • ACR Convergence 2020
“Rheum to Diagnosis”: Uncovering Impediments to Accurate Diagnosis of Non-radiographic Axial Spondylarthritis (nr-axSpA)
Sonam Kiwalkar¹, Atul Deodhar¹ and Richard Howard², ¹Oregon Health & Science University, Portland, OR, ²Spondylitis Association of America, Van Nuys, CA
Background/Purpose: In the US, there is up to a 14-year delay in axSpA diagnosis, which is likely greater for nr-axSpA.1 Impediments to timely diagnosis of…
Abstract Number: 1894 • ACR Convergence 2020
Use of Facebook and Electronic Patient Portal to Identify Axial Spondyloarthritis in Patients with Chronic Back Pain
Yuliya Afinogenova¹, Swetha Alexander², Andrew Haims³ and Abhijeet Danve⁴, ¹Yale University, Orange, CT, ²University of Connecticut, New Haven, ³Yale University, New Haven, CT, ⁴Yale University, Rocky Hill, CT
Background/Purpose: Delay in diagnosis of Axial Spondyloarthritis (axSpA) remains a significant unmet need and can be partially attributed to lack of timely rheumatology referral. Current…
Abstract Number: 0154 • ACR Convergence 2020
Treatment Decision Making Among Axial Spondyloarthritis Patients: Real-World Data from the ArthritisPower Registry
William Nowell¹, Theresa Hunter², Kelly Gavigan³, Jeffrey R Curtis⁴, William Malatestinic⁵, Rebecca Bolce⁵, Jeffrey Lisse⁵, Andris Kronbergs⁵, Carol Himelein⁵, Jennifer Walker⁶ and Jessica Walsh⁷, ¹Global Healthy Living Foundation, New York City, NY, ²Eli Lilly and Company, Indianapolis, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Global Health Living Foundation, New York City, NY, ⁷University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapy has been shown to be effective in the treatment of axial spondyloarthritis (axSpA).1,2 Little is understood about axSpA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].